Skip to content
OpenCapital
Get started

Perspective Therapeutics CATX Shares (Diluted)

Shares (Diluted) at other companies

Eli Lilly logo
Eli LillyLLY
895.9M-0.5%
CytomX Therapeutics logo
CytomX TherapeuticsCTMX
177.3M+103%
Immunome logo
ImmunomeIMNM
113.1M+42.5%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
81.3M+33.1%
Lantheus Holdings logo
Lantheus HoldingsLNTH
65.8M-8.0%
uniQure logo
uniQureQURE
62.7M+18.1%

Other financials

Income statement

See full
Revenue$2.2M+27.3%
Gross profit$738.0K+78.3%
Operating income-$28.3M-29.5%
Net income-$26.2M-44.1%
EPS (diluted)-$0.250.0%

Balance sheet

See full
Cash & equivalents$54.0M+21.5%
Total debt$4.2M+10.9%
Total equity$347.4M+22.1%
Total assets$410.8M+24.7%

Cash flow

See full
Operating cash flow-$31.5M-45.8%
CapEx$6.9M+47.3%
Free cash flow-$38.3M-46.1%

Valuation

See full
Market cap$342.14M+33.2%
Enterprise value$292.34M+35.2%
P/S34.2×+19.6×

Profitability

See full
Gross margin33.1%-7.1pp
Operating margin-292.7%-553pp
Net margin-218.4%-781pp
FCF margin-1,073.3%—

Returns & leverage

See full
Return on equity-35.2%+2.3pp
Debt / equity0×0.0×
Current ratio8.7×-8.3×

Where this comes from

Reported directly by Perspective Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.

The official record: Perspective Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Perspective Therapeutics's shares (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Perspective Therapeutics's shares (diluted)?
Perspective Therapeutics (CATX) reported shares (diluted) of 103.6M in Q1 2026.
How has Perspective Therapeutics's shares (diluted) changed year-over-year?
Perspective Therapeutics's shares (diluted) increased by 43.2% year-over-year, from 72.4M to 103.6M.
What is the long-term trend for Perspective Therapeutics's shares (diluted)?
Over 3 years (2021 to 2025), Perspective Therapeutics's shares (diluted) has grown at a -18.7% compound annual growth rate (CAGR), from 548.1M to 294.7M.
What does shares (diluted) mean?
The weighted-average shares outstanding plus all potentially dilutive shares from stock options, RSUs, convertible securities, and warrants, using the treasury stock method.